parkinson Flashcards
what are the major movement symptoms of the parkinson
(1) Bradykinesia: slowness of voluntary movements
(2) Resting Tremor: involuntary, rhythmic movement of a body part
(3) Rigidity: increased resistance during passive mobilization of body parts
(4) Postural Instability: balance impairments impacting posture
what are the non-motor symptoms in parkinson
- cognitive impairments and dementia: in 80% of patients after 15-20 years
- depressive disorders: in 50% of patients
- sleep impairments: e.g. insomnia in 90% of patients
- gastrointestinal impairments: e.g. swallowing, constipation
what are the Hallmarks of parkinson
occur in the substantia nigra pars compacta:
- decreased dopamine levels
- substantial dopaminergic neuron loss
- cytoplasmic inclusion “Lewy Bodies” present in surviving neurons
what is the Augment Dopamine Production medication
Levodopa (L-Dopa)
what is Levodopa (L-Dopa)
- precursor to dopamine; has been used for decades
- majority of the dose remains outside of the CNS, where peripheral
conversion to dopamine induces adverse effects (e.g. nausea, vomiting
what are the Two major issues of levodopa
- Adverse effect with high dose is dyskinesia
- After long-term use, “wearing-off” may occur
“on” periods and “off” periods
what are the add on approaches to the l-dopa
(i) inhibit peripheral conversion to dopamine
- prevents nausea, vomiting, etc.
(ii) inhibit peripheral metabolism to 3-O-Methyldopa
- increase L-Dopa absorption to the brain
Nissinen, 2010. https://doi.org/10.1016/B978-0-12-381326-8.00001-6
explain (i) inhibit peripheral conversion to dopamine
- inhibitors of dopamine decarboxylase (enzyme also metabolizes L-Dopa)
- these agents themselves do not cross the BBB; only work in the periphery
- most commonly combined with L-Dopa within the same pill
explain this (ii) inhibit peripheral metabolism to 3-O-Methyldopa
- inhibitors of catechol-O-methyltransferase (COMT)
- this agent does not cross the BBB; only works in the periphery
- can be combined with L-Dopa and a dopamine decarboxylase inhibitor
what are the Dopamine Agonists medications for the parkinson
pramipexole and (2) ropinirole
agonists at the D2 family of dopamine receptors
- can be used as an initial treatment, or with L-Dopa in advanced disease
- adverse effects: hallucinations, sleepiness, desire for food, sex, shopping
explain the apomorphine
- agonist at both D1 and D2 families of dopamine receptors
- administered subcutaneously
- indicated for acute “off” periods in patients who are already on a
pharmacological regimen for Parkinson’s disease - adverse effects: same as for pramipexole and ropinirole
sudden falling asleep
nausea - low demand led to cancellation in 2023